Nerandomilast

JASCAYD is a phosphodiesterase 4 (PDE4) inhibitor

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear.

Drug facts

Used for: The treatment of idiopathic pulmonary fibrosis in adult patients. The treatment of progressive pulmonary fibrosis in adult patients. Idiopathic Pulmonary Fibrosis JASCAYD is indicated
for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients. Progressive Pulmonary Fibrosis JASCAYD is indicated
for the treatment of progressive pulmonary fibrosis (PPF) in adult patients.

What it is used for

JASCAYD is a phosphodiesterase 4 (PDE4) inhibitor indicated for: The treatment of idiopathic pulmonary fibrosis in adult patients. The treatment of progressive pulmonary fibrosis in adult patients. Idiopathic Pulmonary Fibrosis JASCAYD is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients.

Progressive Pulmonary Fibrosis JASCAYD is indicated for the treatment of progressive pulmonary fibrosis (PPF) in adult patients.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Nerandomilast; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/nerandomilast
APA 7th: sofidex. (2026, August 3). Nerandomilast. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/nerandomilast
AMA 11th: Nerandomilast. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/nerandomilast

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.